- Home
- GDEV vs KZIA Comparison
GDEV vs KZIA Comparison
Compare GDEV & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDEV | KZIA |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | Cyprus | Australia |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.3M | 186.7M |
| IPO Year | 2021 | 2002 |
Fundamental Metrics
Financial Performance| Metric | GDEV | KZIA |
|---|---|---|
| Price | $11.87 | $10.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 1.3K | ★ 293.3K |
| Earning Date | 05-15-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $8.05 | N/A |
| P/E Ratio | $5.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.00 | $4.86 |
| 52 Week High | $42.20 | $17.40 |
Technical Indicators
Market Signals| Indicator | GDEV | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 35.49 |
| Support Level | $10.65 | $5.15 |
| Resistance Level | $12.00 | $10.49 |
| Average True Range (ATR) | 0.38 | 1.15 |
| MACD | 0.06 | -0.32 |
| Stochastic Oscillator | 61.51 | 2.15 |
Price Performance
Historical ComparisonAbout GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.